ReviewNature reviews. Microbiology2017
Anticancer effects of the microbiome and its products.
Review in Nature reviews. Microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 280 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
280 citing papers in PubMed, 4 syntheses or guidelines pooled it, 518 citations in OpenAlex.
- Causal relationship between 150 skin microbiomes and prostate cancer: insights from bidirectional mendelian randomization and meta-analysis.Frontiers in immunology · 2024Pooled it
- Global research trends on the associations between the microbiota and lung cancer: a visualization bibliometric analysis (2008-2023).Frontiers in microbiology · 2024Pooled it
- Systematic review on the role of the gut microbiota in tumors and their treatment.Frontiers in endocrinology · 2024Pooled it
- Microbiome-gut-brain axis in cancer treatment-related psychoneurological toxicities and symptoms: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Pooled it
- Precision Exercise for Breast Cancer-Related Outcomes: Towards Personalised Training Based on Tumour, Treatment and Patient Characteristics.Sports medicine (Auckland, N.Z.) · 2026Review
- Tumor Topography Remodels TME Signalling via Compartment-Specific Host-Microbiome-Tumor Crosstalk in Hepatoblastoma.Cancers · 2026Article
- Clarifying the nutritional and functional context of gut microbiome signals during chemotherapy for advanced non-small cell lung cancer.Translational lung cancer research · 2026Article
- Targeting the microbiota-miRNA-protease axis: A new therapeutic avenue in melanoma.The FEBS journal · 2026Review
- Decoding the functional landscape and resistome profile of the gut microbiome in the Pangwala tribal community of India.BMC microbiology · 2026Article
- Gut microbiome in advanced non-small cell lung cancer: effect of chemotherapy and impact on efficacy.Translational lung cancer research · 2026Article
- Article
- Innovative approaches in the treatment of hematologic malignancies: the role of CRISPR-engineered microbiomes along the gut-immune axis in immunotherapy development.Cancer cell international · 2026Review
- Causal relationship between GM, immune cells and esophageal adenocarcinoma: a mediation analysis based on MR.Journal of cardiothoracic surgery · 2026Article
- Recent research progress and clinical status of immunotherapy for colorectal cancer.Journal of advanced research · 2026Review
- Article
- Gut microbiota-regulated tryptophan metabolism in breast cancer: mechanisms and therapeutic perspectives.Frontiers in oncology · 2026Review
- Critical role of reproductive tract microbiota and derived metabolites in inflammation, tumor immunity, and tumorigenesis of gynecological cancers: a narrative review.Frontiers in immunology · 2026Review
- From oral dysbiosis to colorectal cancer: reframing fusobacterium nucleatum as an oxidative stress-primed oncobion.Frontiers in cellular and infection microbiology · 2026Article
- Interplay of gut microbiota, immune cells and natural products in reshaping cancer immunotherapy.Frontiers in microbiology · 2026Review
- Exploring the Gut Microbiota as a Promising Target for Breast Cancer Treatment.Current molecular medicine · 2026Review
220 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The human gut microbiome modulates many host processes, including metabolism, inflammation, and immune and cellular responses. It is becoming increasingly apparent that the microbiome can also influence the development of cancer. In preclinical models, the host response to cancer treatment has been improved by modulating the gut microbiome; this is known to have an altered composition in many diseases, including cancer. In addition, cancer treatment with microbial agents or their products has the potential to shrink tumours. However, the microbiome could also negatively influence cancer prognosis through the production of potentially oncogenic toxins and metabolites by bacteria. Thus, future antineoplastic treatments could combine the modulation of the microbiome and its products with immunotherapeutics and more conventional approaches that directly target malignant cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.